CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 100 target
Drug / intervention
engineered immune cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03614650
NCT03614650Phase 1RecruitingOn Track
CompareCT.gov

Antigen-specific Engineered Immune Effector Cells (EIE) Against Gastro-Intestinal (GI) Cancer

Shenzhen Geno-Immune Medical Institute·interventional·Posted Aug 3, 2018·Updated Jun 22, 2026

In Brief

A Phase 1 clinical trial evaluating engineered immune cells for Cancer. Currently recruiting, targeting 100 participants across 1 site.

Detailed Summary

The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20192020202120222023202420252026202720282029
First PostedAug 3, 2018
Enrollment StartJul 1, 2025
Primary CompletionJun 30, 2028
Study CompletionDec 31, 2028
TodayJul 1, 2026
Enrollment to primary: 3.0 yearsPosted 7.9 years agoPrimary completion in 2.0 years

Arms & Interventions

EIE cells to treat cancerexperimental

EIE cells to treat cancer

Biological: engineered immune cells

Interventions

engineered immune cellsbiological

Engineered immune effector cells (EIE)